Anika Therapeutics (ANIK) Liabilities and Shareholders Equity (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $179.4 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $179.4 million, down 5.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $746.8 million (down 15.85% YoY), and the FY2025 annual result was $190.3 million, down 6.15% from the prior year.
• Liabilities and Shareholders Equity retreated to $179.4 million in Q1 2026 per ANIK's latest filing, from $190.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $354.1 million in Q2 2022 and troughed at $179.4 million in Q1 2026.
• A 5-year average of $268.1 million and a median of $263.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity gained 0.46% in 2022, then retreated 29.48% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $349.1 million in 2022, then decreased by 22.48% to $270.6 million in 2023, then retreated by 25.09% to $202.7 million in 2024, then decreased by 6.15% to $190.3 million in 2025, then decreased by 5.72% to $179.4 million in 2026.
• Business Quant data shows ANIK's Liabilities and Shareholders Equity at $179.4 million in Q1 2026, $190.3 million in Q4 2025, and $189.4 million in Q3 2025.